Advocacy and Thought Leadership

The George Institute is focused on effective advocacy and thought leadership to improve health, aligned to our research goals.

We are engaging with key stakeholders, sharing insights and fostering discussions to stimulate debate, guide critical health policy decisions and facilitate evidence-based change.

By working with some of the world’s leading health voices we are amplifying our work in non-communicable diseases (NCDs) and injury and improving systems for prevention and treatment.

Our activities

Faraidoon Haghdoost is a PhD candidate at The George Institute. He is currently researching novel approaches for managing migraine and headache-related disorders. His study focus is the association…
Profile story
The second webinar of our 'Tea with Africa' series focuses on 'Clinical Trials – Are Global trials truly Global? How can LMICs play a more central role?'. The series is part of our Africa Partnership…
Video
To mark International Clinical Trials Day, we asked Laurent Billot, Director of Biostatistics and Data Science at The George Institute for Global Health, and internationally recognised clinical…
News
A lot of progress has been made in Africa towards reducing deaths from communicable diseases, and there are opportunities to do same for non-communicable diseases. Staff and students at The George…
Profile story
This reflection started as a response to discussions with Franklin Women and the High Blood Pressure Research Council Australia in early December - I was keeping notes on my phone about how the way…
Profile story
Anna is a biostatistician at The George Institute, Australia. She specialises in using data to explore and understand health patterns in high-risk or vulnerable populations to inform treatments,…
Profile story
The George Institute for Global Health invites you to mark International Women’s Day on Wednesday 9 March 2022 from 1pm to 2pm (AEDT). Join us online for a panel discussion with notable experts…
Event
Strong evidence exists to demonstrate the benefit of SGLT2 inhibitor use for indications beyond diabetes management, including kidney disease and heart failure, however the uptake to use SGLT2…
Event
High blood pressure is one of the most serious risk factors for cardiovascular disease (e.g. stroke, heart failure and coronary heart disease (CHD)), the leading cause of death worldwide. High blood…
Policy and Practice Reports
The George Institute for Global Health is pleased to contribute to the Consultation for the development of the CFS Voluntary Guidelines on Gender Equality and Women’s and Girls’ Empowerment in the…
Policy and Practice Reports